Corvus Pharmaceuticals (CRVS) to Release Earnings on Monday

→ Does this make you sick? (From Allegiance Gold) (Ad)

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) is scheduled to announce its earnings results after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.

Get Corvus Pharmaceuticals alerts:

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last issued its quarterly earnings results on Tuesday, March 19th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). On average, analysts expect Corvus Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Performance

NASDAQ:CRVS traded up $0.19 during mid-day trading on Friday, hitting $1.92. The company had a trading volume of 360,645 shares, compared to its average volume of 202,584. Corvus Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $4.19. The business's fifty day moving average is $1.81 and its two-hundred day moving average is $1.77. The firm has a market cap of $94.15 million, a P/E ratio of -3.40 and a beta of 1.05.

Ad Insiders Exposed

Has Trump Finally Gone Too Far?

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Corvus Pharmaceuticals in a research note on Monday, April 1st. Oppenheimer cut their target price on Corvus Pharmaceuticals from $8.00 to $7.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 20th. Finally, Mizuho reissued a "neutral" rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 27th.

Get Our Latest Stock Analysis on CRVS

About Corvus Pharmaceuticals

(Get Free Report)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.

Should you invest $1,000 in Corvus Pharmaceuticals right now?

Before you consider Corvus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.

While Corvus Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report